Eli Lilly | LLY - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
AbbVie USD 5.57B 2.9B 2026-03
Abbott USD 2.39B 27M 2026-03
ALKERMES USD -61.93M 122.3M 2026-03
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Baxter International USD -756M 877M 2025-12
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Coherus Biosciences USD -46.35M 90.86M 2025-12
Drreddys Laboratories INR 15.43B 1.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.46B 569M 2025-09
J&J USD 7.82B 2.86B 2026-03
Medtronic USD 2.45B 1.04B 2026-03
Merck USD 3.42B 3.32B 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 802M 2026-03
Novartis USD 5.17B 637M 2025-09
Novo Nordisk DKK 33.8B 3.23B 2025-06
Perrigo USD -1.33B 1.35B 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 61.81M 7.32M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
United Therapeutics USD 444M 6M 2025-12
Zoetis USD 761M 126M 2025-12